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Abstract. Currently, pharmaceutical research is directed wide range for developing new
drugs for oral administration to target disease. Acyclovir formulation is having common
issues of short half-life and poor permeability, causing messy treatment which results in
patient incompliance. The present study formulates a lipid polymeric hybrid nanoparticles for
antiviral acyclovir (ACV) agent with Phospholipon® 90G (lecithin), chitosan, and
polyethylene glycol (PEG) to improve controlled release of the drugs. The study focused
on the encapsulation of the ACV in lipid polymeric particle and their sustained delivery. The
formulation developed for the self-assembly of chitosan and lecithin to form a shell
encapsulating acyclovir, followed by PEGylation. Optimisation was performed via Box-
Behnken Design (BBD), forming nanoparticles with size of 187.7 ± 3.75 nm, 83.81 ± 1.93%
drug-entrapped efficiency (EE), and + 37.7 ± 1.16 mV zeta potential. Scanning electron
microscopy and transmission electron microscopy images displayed spherical nanoparticles
formation. Encapsulation of ACV and complexity with other physical parameters are
confirmed through analysis using Fourier transform infrared spectroscopy, differential
scanning calorimetry, and X-ray diffraction. Nanoparticle produced was capable of achieving
24-h sustained release in vitro on gastric and intestinal environments. Ex vivo study proved
the improvement of acyclovir’s apparent permeability from 2 × 10−6 to 6.46 × 10−6 cm s−1.
Acyclovir new formulation was achieved to be stable up to 60 days for controlled release of
the drugs.
KEY WORDS: acyclovir; hybrid nanoparticles (LPHNs); Box-Behnken design; in vitro; ex vivo
permeation.
INTRODUCTION
Viral diseases are emerging as a major cause for the
mortality of the human life. Emergence of these infectious
virus causes a pandemic and an epidemic from time to
time, disturbing normal life. Virus strains and their
classifications are vast, their transmission (e.g. zoonotic
spread) makes them additional biologically vulnerable to
human. The recent issues of the occurrence of endangered
coronavirus (Covid-19) for threatening the world. Some
examples of cross-species virus transmission are Ebola,
severe acute respiratory syndrome (SARS), chicken pox,
and herpes simplex virus (HSV). The herpes simplex virus
(HSV) is from the family of Herpesvirida and mainly
forms two main types (HSV-1 and HSV-2). HSV-2 infected
more than 400 million people at the age of 15–59
worldwide with genital herpes with sexually transmitted
and also lifelong incurable disease HSV-2 (1,2). Currently,
the therapeutic drugs available are acyclovir, valaclovir,
and famciclovir, in which acyclovir is referred as the most
widely used drug to control disease. Acyclovir (ACV) is
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acyclic guanosine analog of purine nucleoside, (guanine
substituted at (2-hydroxyethoxy) methyl) at 9 position (2-
amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one) (2). It
is mostly involved in the treatment of HSV-1 and HSV-
2, given orally daily with a dose of 400 to 800 mg (2–3)
(3). In the Biopharmaceutical Classification System (BCS)
class III drugs, the large dose and frequent administration
are due to acyclovir having poor aqueous solubility
(1.5 mg/mL) and poor permeabi l i ty (0.12 ~ 2 ×
10−6cm s−1), rendering acyclovir to have low oral
bioavailability (10 ~ 30%) and short half-life (3 h) with
molar mass 225.21 g/mol (4–8). Oral acyclovir has a
narrow absorption window, which is from the stomach to
duodenum (9). The low absorption depicts the need for a
delivery system that could release effectively in either or
both gastric and intestinal environment to target the
disease.
Several attempts have been made to enhance the
delivery of oral acyclovir using polymeric mediated
nanocarriers. Some of the delivery systems are interpen-
etrating polymeric network which is based on the close
contact and molecular-scale interaction between different
polymers to encapsulate the drug (10), poly (lactide-co-
glycolides) (PLGA) nanoparticles (2), and chitosan ionic
gelation with sodium tri-phosphate (TPP) (11–14). The
use of polymers and amphiphilic molecules has con-
stantly been involved in the delivery of hydrophilic and
lipophilic molecules. Lecithin (phosphatidylcholine) is
used in various nanocarrier-designed formulations like
micelles, liposomes, and lipid nanoparticles (15–16). Lec-
ithin is not only used due to its safe and biocompatibility
properties, but also because it is the solubilising carrier
for poorly water-soluble drugs (17). Lecithin and chitosan
can form spherical nanoparticle via supramolecular self-
organising interaction (12). Concept of PEGylation in oral
delivery is also well studied for drug release. Mariyam
et al. introduced that PEGylated dendrimer-based
5fluorourasil (5FU) gave better loading and slower release
of 5FU than non-PEGylated polymer (18). Moreover, the
use of polyethylene glycol (PEG) imparts stealth proper-
ties on nanoparticles (19), reducing the tendency to be
eliminated by the reticuloendothelial system (RES), im-
proving bioavailability and half-life of drug (20). The
hydrophilic properties of PEG could prevent interaction
with other nanoparticles via sterical hindrance, improving
the stability of nanoparticles (21). PEG is also claimed to
enhance mucoadhesive of nanoparticles (22).
The present study aimed to design a PEGylated lipid
polymeric nanoparticle system, utilising chitosan, lecithin,
and poly (ethylene glycol) (PEG) 2000 that was
hypothesised to produce nanoparticles with high encap-
sulation and good permeability, accompanied by a
sustained release profile. PEGylated acyclovir-loaded
lecithin-chitosan nanoparticles (PALNs) were formulated
and optimised, and the physicochemical properties of
PALN were characterised for stability of the nanoparti-
cles. Simulated gastric fluid (SGF) and simulated intesti-
nal fluid (SIF) were used to study the in vitro drug
release of PALN. In contrast, rabbit intestine was used
to evaluate the ex vivo permeation performance for the
controlled release of the drugs for 60 days.
MATERIALS AND METHODS
Materials
Acyclovir (ACV) was acquired from Pharmaniaga Re-
search Centre Sdn. Bhd. (Malaysia). Phospholipon® 90G
(lecithin) was bought from Lipoid GmbJ, Mattermannallee,
Switzerland. Chitosan, propylene glycol (PG), and polyethyl-
ene glycol (PEG-2000, MW: 1900–2200) were purchased from
Merck Sdn. Bhd (USA). Dialysis bag-110 (molecular weight
cut-off (MWCO): 12,000–14,000 Da) was purchased from
HiMedia Laboratories Pvt. Ltd. (India). Rabbit intestinal sac
was obtained as a gift from SARSHA Riding Centre. HPLC-
grade Acetonitrile was procured from Fisher Scientific Inc.
(Malaysia). Water is purified using a MilliQ® Integral Water
Purification System with a conductivity of 15 MΩ. Other
chemicals were of analytical reagent grade.
Experimental Design
A 3-factor, 3-level, 17-run Box-Behnken Design (BBD)
was adopted to generate polynomial models for the optimi-
sation process of the drug. Three determining factors were
the amount of lecithin (X1), chitosan (X2), and PEG 2000
(X3) as shown in Table I. Dependent variables to be
optimised were entrapment efficiency (EE%) (Y1), zeta
potential (mV) (Y2), and particle size (nm) (Y3). Design-
Expert® Software Version12 was employed to establish main
effects, interaction effects, and quadratic effects from inde-
pendent variables, and provide the solution for optimised
formulation. The nanoparticle formulations involved, includ-
ing five centre points, are tabulated in Table II. All
experimental results measurement was analysed in triplicate
and expressed as mean ± standard deviation and p < 0.05 was
considered as significant for the data.
Preparation of Acyclovir-Loaded Lecithin-Chitosan
Nanoparticles
ALN was prepared by the method reported by Sedef and
group with little modification (15). An appropriate amount of
lecithin and chitosan was weighed, as shown in Table II.
Chitosan was dissolved in 15 mL of 0.1% v/v acetic acid
followed by heating to 60°C. Lecithin prepared was dissolved
in an organic solvent consisting of 2.5 mL methanol, 2.5 mL
chloroform, and 2 mL PG. An amount 15 mg of ACV was
Table 1. Variables and Their Levels in Box-Behnken Design
Factors Factor levels
− 1 (low) 0 (medium) + 1 (high)
A: lecithin (mg) 100 200 300
B: chitosan (mg) 10 15 20
C: PEG 2000 (mg) 20 30 40
Dependent variables Constraints
Y1 = entrapment efficiency (%EE) Maximise
Y2 = particle size (nm) Minimise
Y3 = zeta potential (mV) Maximise
285 Page 2 of 15 AAPS PharmSciTech (2020) 21: 285
added after full solubilisation of lecithin, followed by
sonication to solubilise all acyclovir. The lecithin/ACV
solution was then added dropwise into chitosan solution
under vigorous magnetic stirring. Finally, the nano-suspension
was probe sonicated for 4 min.
PEGylation of ALN
PEGylation was performed by modifying an established
method by Arya et al. (23). Prepared PEG 2000 solutions
were 200 mg/mL, 300 mg/mL, and 400 mg/mL. One millilitre
of the solution was added into nano-suspension formed under
Section C. The suspension was agitated at moderate intensity
for 30 min, followed by probe sonication with 30% amplitude,
pulse on/off the rate of 10 s/5 s, for 2 cycles. The formulated
particles were centrifuged and supernatants containing any
trace of free ACV were separated for the purification of drug.
Final product PEGylated ACV-loaded lecithin/chitosan
Nanoparticles (PALNs) were stored for further analysis to
study the controlled release of drugs.
Optimisation of Formulation
Drug Entrapment Efficiency Analysis
Amount of encapsulated ACV in nanoparticles was
identified indirectly in high-performance liquid chromatogra-
phy (HPLC) (24). Agilent 1260 Series HPLC system fitted
with a photodiode array detector (DAD), and use Thermo
Fisher Syncronis C-18 (5-μm particle size, 150 × 4.60 mm
diameter) column. A fixed injection volume of 20 μl per
sample, a column temperature of 25°C, and a wavelength of
254 nm were set. The mobile phase used was acetonitrile and
pH 6.74 water (10:90, v/v), which was set at an isocratic flow
rate of 0.5 ml/min for 10-min run time. Equation (1) showed a
calibration curve that fit over the range 100–500 μg/ml with a
correlation coefficient of r2 = 0.99990.
y ¼ 117:88803xþ 43:82506 ð1Þ
where y represented the peak area in a milli-absorbance unit
(mAu) and x represented the ACV concentration (mg/ml).
In evaluating the entrapment efficiency (EE), PALNs
prepared were stored in − 80°C freezer for 24 h. Then PALNs
were thawed and isolated by centrifugation at 48,000×g at 4°C
for 20 min. The supernatants consisted of the free drug were:
EE %ð Þ ¼ Mtotal–Mfree
 
=Mtotal 100% ð2Þ
where EE was the entrapment efficiency, and Mtotal and Mfree
were a total mass of ACV added and free ACV in
supernatant respectively.
Zeta Potential Measurement Particle Size and Poly-Dispersity
Index
Particle size, Poly-Dispersity Index (PDI), and zeta
potential were determined by DelsaMax PRO Zeta Potential
Dynamic Light Scattering Analyzer (Beckman Coulter,
USA). To measure the size and zeta potential, 0.1 ml of
prepared particles was diluted with 2.0 ml of deionised water
loaded in flow cell and scanned for particles. The measure-
ment was done in a 173° scattering angle. The experiment was
done with a setting of 25 ± 0.5°C.
Characterisation of Optimised PALN Formulation
Morphological Analysis
Morphology study of the nanoparticles was carried out
using scanning electron microscopy (SEM) (4). The formula-
tion was lyophilised and further dried using vacuum oven for
30 min and the powder was uniformly spread on the coverslip
and further coated with platinum using 208HR High-
Resolution Sputter Coater (Ted Pella, INC, CA, USA).
Coated sample was then inserted into the specimen chamber
and scanned using TM 3030 Plus scanning electron micro-
scope (Hitachi, Tokyo, Japan), at 5 kV.
High-Resolution Transmission Electron Microscopy
The optimised formulation was visualised by high-
resolution transmission electron microscopy (HRTEM). The
formulation was diluted with water in ratio of (1:50) and
placed on the copper film–coated grid, with a diameter of
3.05 mm and 400 mesh size (Ted Pella, CA, PELCO® 400
Mesh Grids). After placing the particle, they were air dried
for 15 min and any access of water was removed using a filter
paper. The analysis was done by using a Tecnai G2 20 Twin
transmission electron microscope (FEI Company, Oregon,
USA).
Differential Scanning Calorimetry
Thermal properties of optimised formulation were
analysed using differential scanning calorimetry (DSC) 214
Polyma differential scanning calorimeter (NETZSCG-
Table 2. Box-Behnken Experimental Design
Formulation Independent variable level
Lecithin (X1) Chitosan (X2) PEG 2000 (X3)
PALN1 0 0 − 1
PALN2 0 0 + 1
PALN3 − 1 − 1 0
PALN4 + 1 + 1 0
PALN5 − 1 − 1 − 1
PALN6 − 1 − 1 + 1
PALN7 + 1 + 1 + 1
PALN8 0 0 0
PALN9 0 0 0
PALN10 0 0 0
PALN11 + 1 + 1 − 1
PALN12 0 0 − 1
PALN13 0 0 + 1
PALN14 − 1 − 1 0
PALN15 + 1 + 1 0
PALN16 0 0 0
PALN17 0 0 0
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Gerätebau GmbH, German). Samples used included lecithin,
chitosan, PEG 2000, optimised formulation, pure acyclovir,
and a blend of acyclovir, chitosan, lecithin and PEG 2000
(physical mixture, PM). The optimised formulation was dried
in SHEL LAB SVAC2-2 vacuum oven (Sheldon Manufactur-
ing Inc., USA) under 35°C and 25 in. Mercury (Hg) before
analysis (16). Black alumina was used as a reference.
Nitrogen gas purge rate was 20 mL/min. The analysis was
conducted with settings shown in Table III. All the scanned
samples were analysed in triplicate to plot the data.
X-Ray Diffractometry
The crystallinity of PALNs synthesised was studied
through the sharpness of peak in the XRD spectra by X’Pert3
Powder X-Ray Diffractometer with X’Celerator (Malvern
Panalytical, UK). Samples used were lyophilised PALNs,
pure ACV, and PM. Samples were radiated with CuK α
radiation at 45 kV and 140 mA. 2θ scan range from 0° to 60°,
with 3°/min scanning rate, and 0.05° step size were set (17).
All the tests were performed in triplicates.
Attenuated Total Reflection-Fourier Transform Infrared
Spectrometer
Compatibility study was conducted using Nicolet iS50
FT-IR Spectrometer (Thermo Fisher Scientific Inc., Waltham,
MA). Samples used included pure acyclovir, lecithin, chito-
san, PEG 2000, optimised formulation, and PM. Before
analysis, optimised formulation was vacuum-dried at 35°C
and − 25 in Hg (17). The analysis was done with sixteen scans
at scanning range of 600 to 4000 cm−1.
Stability Study
A replicate of optimised PALN was prepared without
lyophilisation and assessed for short-term physical stability
for 60 days based on ICH guidelines. The sample was stored
in 4°C chiller throughout the study period. Nanoparticle size
of the sample was measured by using the method as described
in section F at an interval of 0th, 15th, 30th, 45th, and 60th
days. A p < 0.05 was considered as significant for the obtained
data.
In Vitro Drug Release Profile
In vitro drug release profile was conducted on the
optimised formulation by employing a dialysis bag method
with USP apparatus II. Two sets of dialysis bag (MWCO:
14,000 Da) of suitable length to accommodate the sample
were prepared and immersed in 37°C ultrapure water for
30 min for stabilisation. One end of the dialysis bags was tied
securely with thread. Then 4 mL of optimised formulation
with ACV concentration of 1 mg/mL was injected into each
dialysis bag. Another end of the dialysis bags was then tied
securely with a thread. The dialysis bags were kept in sink
condition in two separated vessels of a RC-8DS dissolution
tester (Sinopham Co., Ltd., China) filled with 400 mL of
pH 1.2 hydrochloric acid buffer (SGF) and 400 mL of pH 6.4
phosphate buffer saline (SIF) respectively. Dissolution tester
was set for 70-rpm rotation and 37°C water bath. One
millilitre of sample was taken in triplicate at 0.5 h, 1 h, 2 h,
4 h, 8 h, 12 h, and 24 h. The same volume of fresh medium
was re-filled into the corresponding vessel. Samples were
analysed with HPLC method as described in section E.
Another calibration curve with a smaller range from (1) was
generated to ensure the accuracy of ACV concentration
derived from peak area. Equation (3) showed a calibration
curve that fit over the range of 5 to 50 μg/mL with r2 of
0.99964.
y ¼ 125:32389xþ 79:70511 ð3Þ
The drug release profile of optimised formulation was
plotted with a cumulative percentage of ACV released
against time. Drug release data was fitted into one of the
releasing models which were zero order, first order, Higuchi,
Korsmeyer-Peppas, and Hixson-Crowell releasing model. A
best model kinetic fit describing drug release of the formula-
tion was selected according to the coefficient of determination
(r2) that calculated with aid from Microsoft Excel. Equation
(4) was used as a formula for the cumulative percentage of
drug-released calculation.
DR %ð Þ ¼ Mreleased=Mtotalð Þ 100% ð4Þ
where DR was the cumulative percentage of drug released,
and Mreleased and Mtotal were mass of acyclovir released and
total mass of acyclovir in formulations used respectively.
Study of Ex vivo Intestinal Permeability
Ex vivo study was performed according to an established
method (25) with modification. The study was done using
New Zealand white rabbit of age 5–6 months. The rabbit
intestine sac was cleaned with cold saline. It was cut into
several 9.5-cm-long segments. The intestine segment was tied
up securely with thread at one end, followed by the
introduction of 2 mL of optimised formulation with 1 mg/
mL of ACV concentration into the intestinal opening. The
other end was then tied up securely with thread. The rabbit
intestine sac containing the formulation was kept in sink
condition in a beaker containing 80 mL of pH 7.4 PBS with
1% m/v sodium lauryl sulphate (SLS) at 37°C as releasing
Table 3. DSC Setting for Thermal Analysis of Each Sample
Sample Heating range (°C) Heating rate (°C/min)
Initial Final
Optimised formulation 0 320 5
Lecithin 10 100 3
Chitosan 50 320 10
PEG 2000 0 320 10
Acyclovir 50 320 10
Physical mixture 0 320 10
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medium. The beaker was closed with cover to prevent
evaporation of releasing medium. One millilitre of the sample
was taken at 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, and 10 h in triplicate,
and an equal amount of fresh releasing medium was
replenished. Samples were analysed with HPLC method as
described in section E, and Eq. (3) was used for calculation of
ACV concentration in the samples.
Drug intestinal permeability profile of optimised PALN
formulation was plotted with a cumulative amount of ACV
permeated into releasing medium against time. Cumulative
percentage of drug permeated was calculate with Eq. (5)
DP %ð Þ ¼ Mmedium=Mtotalð Þ 100% ð5Þ
where DP was the cumulative percentage of drug permeated
and Mmedium was the mass of acyclovir in releasing medium.
Apparent permeability of the formulation as a function
of the mucosal surface area was calculated by Eq. (6). In
contrast, Eqs. (7) and (8) were used to calculate apparent
permeability coefficient and steady-state flux, and Jss of






  ¼ dQ=dtð Þ 1= AC0ð Þ ð7Þ
where Papp was the apparent permeability coefficient,
dQ/dt was the slope for the graph of the cumulative amount
of ACV permeated against time in unit of mg/h, A is the
surface area of intestinal tissue where the permeation of
nanoparticles occurred in the unit of cm2, and C0 gave an
initial concentration of ACV in the intestinal sac that was
1 mg/mL (equivalent to 1 mg/cm3).
Jss mgcm−2s−1
  ¼ PappC0 ð8Þ
RESULTS AND DISCUSSION
Mechanism of PALN Formation
PEGylated lipid polymeric nanoparticle (PALN) forma-
tion hypothesis is shown Fig. 1. The method follows the self-
organising interaction between the combination of lecithin,
chitosan, and PEG 2000 (15). ACV, being polar in nature,
attracts the hydrophilic head of lecithin (26), while randomly
dispersing in the solvent for fabricating nanoparticles. The
lecithin/ACV solution was added into chitosan solution, the
electrostatic interaction between chitosan, and lecithin led to
the formation of chitosan hydrophilic shell layer surrounding
the internal core of lecithin and ACV. The combination of
chitosan and lecithin permitted the formulation of stiff and
stable nanostructure (27). Hydrogen bonding and physical
entanglement might also occur between lecithin and chitosan
(28).
PEG can provide stealth property on nanoparticles to
avoid RES elimination and prolong their circulation time
(29). Protonation on chitosan-free amino group in the acidic
environment caused it to be positively charged. The dipole-
dipole or hydrogen bonding between chitosan shell and PEG
became stronger than intra-molecular or intermolecular
hydrogen bonding of chitosan chain and allowed PEG
grafting onto it due to interaction between amine or amide
nitrogen of chitosan, and hydroxyl and etheric oxygen of
PEG (30). Probe sonication was employed to reduce particle
size as well as improving uniformity of size. PALNs formu-
lated exhibited a pale white appearance with soapy texture.
Pale white colour resulted from the massive amount of
nanoparticles formed, while the frothy white texture was
due to the presence of PEG 2000 in the formulation.
Optimisation of Formulation
The Box-Behnken design with 3 × 3 factorial design
generated 17 trail with 5 centre points runs for the prepara-
tion of PEGylated lipid polymeric nanoparticles (PALNs) as
shown in Table II. The optimisation data shows that the
concentration of independent factors lecithin (A), chitosan
(B), and PEG 2000 (C) exerts an individual negative and
positive effect on the dependent factors i.e. entrapment
efficiency (Y1), particle size (Y2), and zeta potential (Y3).
The best fitted equation was selected as quadratic for all the 3
dependent factors. The effect was shown through 3D
response surface depicting the interaction between indepen-
dent variables and dependent factors as shown in Fig. 2.
Before the BBD development, some preliminary studies were
conducted using the ratio of the lecithin and chitosan was
selected. The aim was to get the maximum entrapment
efficiency and minimum range for particle size. The probe
sonication was selected at 4 min, as in our preliminary studies,
it was concluded that high sonication with leaded to breakage
in the particle and 1-–2-min sonication produced particles
with large diameters.
Drug Entrapment Efficiency
The EE is shown in Table IVand Fig. 2 a represented the
graphical presentation of EE for all formulations. The results
obtained for the drug EE ranged from 68 to 87%. The use of
sonication for solubilisation of ACV in organic solvent
allowed it to be correctly attached to lecithin and get
encapsulated into nanoparticles formed.
Design-Expert software generated Eq. (9) that expressed
the effect from independent factors, which were the amount
of lecithin (X1), amount of chitosan (X2), and amount of PEG
2000 (X3) on drug entrapment efficiency of the formulation.





A positive value for coefficient indicates the increment in
the factor results in an appropriate improvement in the
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response and vice versa. The equation with adjusted R2 of
0.9398 indicates a good fit. Interaction between the factors
affecting drug entrapment efficiency was as shown in Fig. 3 a–
c; it is to be noted that the X1 and X2 in the figures indicate
the X-axis instead of the independent factors.
Figure 3 a showed the increment of drug entrapment
efficiency by increasing lecithin amount and decreasing
chitosan. It is also observed that drug entrapment efficiency
reduced at level 1 of lecithin, as micelle formed when lecithin
concentration exceeds critical micelle concentration which
could affect the encapsulation process. Lowering the amount
of lecithin also led to poor encapsulation efficiency as less
available hydrophilic heads to be attracted by ACV (26).
Increment in chitosan concentration amount improved self-
assembling process between chitosan and lecithin, which also
resulted in weakly attraction between ACV and lecithin and
ACV will not be entrapped. It is noticed that the interaction
effects between lecithin and chitosan have the most substan-
tial impact on entrapment efficiency.
Figure 3 b and c showed the interaction between PEG
2000 as well as between chitosan and lecithin on entrapment
efficiency was weaker when compared with lecithin and
chitosan. EE decreases slightly with an increment of PEG
2000 amount, which might be due to the interaction between
the PEG 2000 and chitosan, as it affects the electrostatic
interaction between lecithin and chitosan, causing the tight
junction to be disrupted upon mixing, resulting in drug
leaking. The disruption was attributed to the ability of PEG
2000 to enter the loosely packed structure (31). A suitable
amount of lecithin (X1) should be used in pair with sufficient
but not excessive amount of chitosan (X2), and less PEG 2000
(X3) for high EE.
Zeta Potential Measurements
Zeta potential for all formulations was determined and
tabulated in Table IV as observed values. Figure 2 b showed
the graphical presentation of zeta potential measurement for
17 formulations. The zeta potential ranged from + 20.77 ± 5.59
to + 50.47 47 ± 1.65 mV. The zeta potential was mainly
determined by lecithin and chitosan used. However, PEG
2000 as a polymer grafting on the lecithin-chitosan core-shell
structure might be impacting the stability of the nanoparticle.
The values can be used as an indicator that all the prepared
hybrid nanoparticle formulations were highly stable. Using
Design-Expert software, the relationship between the used
amount of lecithin, chitosan, and PEG 2000 on zeta potential
can be explained using Eq. (10) with a high R2 value of
0.9294.
Y2 ¼ 28:09–3:57X1 þ 8:68X2–7:16X3 þ 0:42X1X2 þ 1:83X1X3 þ 2:08X2X3 þ 1:51X21þ
6:7X22 þ 1:84X23
ð10Þ
Figure 3 d showed positive linear relationship between
zeta potential and amount of chitosan used for developing the
nanoparticles. The relationship was predictable since chitosan
dissolves in an aqueous solvent, exhibiting net positive
charges due to the protonated amine group (30). When the
amount of lecithin used decreases, the zeta potential
increases, proving that negatively charged lecithin had
reacted with positively charged chitosan, producing a nega-
tive effect on zeta potential. The same trend can be seen in
Fig. 3 e, where PEG 2000 with a surface charge of − 2 to −
7 mV also had a negative effect on zeta potential, but to a
lower extent to that of lecithin (32). It can be seen that
chitosan was capable of producing formulation with zeta
potential greater than 50 mV. Still, the use of PEG 2000 and
lecithin, or to be exact, the electrostatic interaction between
chitosan and other components, causes the reduction of zeta
potential. Figure 3 f further supported the point that lecithin
and PEG 2000 were responsible for zeta potential decrement.
When a higher proportion of PEG2000 (40 mg) and lecithin
(300 mg) was used, the zeta potential significantly decreases
in the nanoparticles.
Particle Size and PDI Analysis
Particle size and PDI obtained from all 17 formulations
were recorded in Table IV as observed values and illustrated
in Fig. 2 c. The particle size ranged from 155.31 ± 6.87 to
264.82 ± 4.33 nm, with PDI ranged from 0.179 ± 0.03 to 0.429
± 0.12. In overall, the results were accepted as it is capable of
Fig. 1. Schematic diagram for PALNs formation. a Hydrophilic head attracts towards the
polar head. b Lecithin-chitosan leads to electrostatic interaction and formation assembly. c
Self-organisation between the lecithin, chitosan, and PEG 2000
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exhibiting enhanced permeability and retention (EPR) effect.
Equation (11) describes the effect of three independent
factors on particle size, with high r2 value of 0.9162 to prove
that the equation is reliable.
Y2 ¼ 162:83þ 16:23X1 þ 18:39X2 þ 16:72X3 þ 14:47X1X2–14:07X1X3–15:65X2X3 þ
17:39X21 þ 26:7X22 þ 47:32X23
ð11Þ
We observed that particle size was significantly impacted
by amount of lecithin, chitosan, and PEG 2000 used, as shown
in Fig. 3 g–i.
The particle size of PALN increased with the amount of
lecithin and chitosan used in the nanoparticles. As more
lecithin and chitosan were used, more drugs attracted and
entrapped in the core, forming bulkier nanoparticle. The
nanoparticles formed showed a size smaller than 200 nm, as a
proven larger proportion of smaller nanoparticle size area in
Fig. 4. To decrease the amount of chitosan injudiciously was
not preferred as it might be insufficient to form a complete
spherical structure with lecithin, which was bulkier with
attached drug. Thus, lecithin to chitosan ratio must be adjust
to ensure complete self-assembling process as it leads to rigid
spherical nanoparticle occupying less space. On the other
Fig. 2. Graphical presentation of a drug entrapment efficiency, b zeta potential, and c particle size
and PDI PALNs formulation
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hand, increment in PEG 2000 thickens the layer on PALN,
resulting in size increment (32). It is also observed that
without sufficient PEG 2000, the drug residence time in
systemic blood circulation might not be able to be signifi-
cantly prolonged for nanoparticles.
Statistical Analysis of Experimental Data by Design-Expert
Software
Table V summarised quadratic equation used in describ-
ing the effect of three independent variables on three
dependent variables. All factor with (p value< 0.05) were
considered as significant. The expected values for Y1, Y2, and
Y3 was shown in Table IV. Due to negligible difference
between observed and predicted value, a quadratic Eqs. (9),
(10), and (11) can serve as a good indicator of behaviour and
interaction relationship between the independent factors.
The measurements considering for all obtained and
software’s recommendation, formulation PALN1 with high
EE of 83.81 ± 1.93%, the particle size of 187.7 ± 3.75 nm, and
PDI of 0.238 ± 0.01. The values of PALN1 were selected due
to its higher EE and optimum size. The zeta potential of +
37.70 ± 1.16 mV of PALN1 was found to be very stable. The
ratio of lecithin to chitosan for the optimised formulation is
exactly 20:1, which was known to be the perfect proportion of
both materials to get a small-sized nanoparticle with spherical
shape (33).
Characterisation of Optimised Formulation
Scanning Electron Microscopy
The SEM images revealed a round and spherical shape
morphology with a smooth surface of the nanoparticles (Fig.
4a, b) (34).
High-Resolution Transmission Electron Microscopy
Figure 4 c shows the range of particle size from 172 to
198 nm. The HRTEM measurement was in the agreement
with dynamic light scattering (DLS) measurement of PALN1
particle size of 187.7 ± 3.75 nm. Also, the figure shows a two-
layer structure of nanoparticles, which corresponds to the
formation of chitosan shell layer around the lecithin core (35).
Differential Scanning Calorimetry
Figure 5 a lecithin showed a low-intensity endothermic
peak at 47.2°C, which was the chain melting transition point
where it transformed into a liquid crystalline form from a gel
form with enhanced ability to act as a drug carrier (36). Two
endotherms were observed for chitosan, where 83.8°C was
attributed to water loss and polymeric chain decomposition at
303.7°C (37). PEG 2000 endothermic peaks at 53.5°C,
indicating melting process of the sample (36).
ACV had four thermal effects shown in Fig. 5 a. The
analysis for ACV used was ACV polymorph form VI, with 1:2
ratio of ACV to water. The first endothermic peak at 116.5°C
was assigned to the dehydration process. It leads to
recrystallisation of ACV form VI to ACV form V, which
undergoes a phase transition to IV at 174.6°C. Further
heating leads to endotherm at 255.7°C, indicating ACV
melting point (MP). Last exothermic peak at 259.1°C was
assigned to the exothermic decomposition of the ACV (38).
The physical mixture for the first endotherm was
assigned to the lecithin and PEG2000. ACV endothermic
peak diminished but a new peak emerged at 151°C. It might
be due to molecular interaction between drug, lecithin and
chitosan. The interaction causes ACV to have decreased
crystallinity and increased amorphous properties of acyclovir,
or turned into semi-solid form, or dissolution in the matrix
melt (39). For PALN1, peak diminishments of lecithin,
Table 4. Observed and predicted value of encapsulation efficiency (Y1), particle size (Y2) and zeta potential (Y3) of formulations in the
Box-Behnken design
Sample EE, % (Y1) Zeta potential, mV (Y2) Particle size, nm (Y3) PDI
Observed Predicted Observed Predicted Observed Predicted
PALN1 83.81 ± 1.93 84.84 37.70 ± 1.16 37.19 187.7 ± 3.75 186.09 0.238 ± 0.01
PALN2 82.15 ± 6.26 81.07 48.33 ± 1.93 50.39 264.8 ± 12.21 254.17 0.429 ± 0.12
PALN3 77.28 ± 0.58 78.00 43.73 ± 5.78 44.00 177.7 ± 5.23 180.51 0.216 ± 0.01
PALN4 83.44 ± 2.47 82.77 35.03 ± 1.76 33.20 231.7 ± 6.32 241.17 0.228 ± 0.02
PALN5 74.17 ± 6.10 72.42 31.37 ± 1.48 31.60 187.9 ± 9.56 186.76 0.243 ± 0.01
PALN6 68.45 ± 1.79 68.81 50.47 ± 1.65 48.13 186.8 ± 8.98 194.69 0.232 ± 0.02
PALN7 70.17 ± 9.14 71.92 42.07 ± 1.21 41.83 254.8 ± 15.45 256.00 0.237 ± 0.00
PALN8 84.72 ± 1.90 85.44 25.47 ± 1.33 28.09 156.4 ± 8.98 162.83 0.314 ± 0.01
PALN9 86.67 ± 3.27 85.44 31.17 ± 1.33 28.09 178.7 ± 10.54 162.87 0.179 ± 0.03
PALN10 84.67 ± 3.56 85.44 27.63 ± 2.94 28.09 166.1 ± 3.65 162.87 0.244 ± 0.01
PALN11 83.97 ± 1.52 83.61 21.30 ± 2.48 23.63 198.1 ± 4.78 190.29 0.167 ± 0.02
PALN12 83.57 ± 2.03 84.64 20.77 ± 5.59 18.70 240.2 ± 4.56 250.82 0.208 ± 0.03
PALN13 74.13 ± 4.69 73.10 39.73 ± 1.60 40.24 254.7 ± 16.87 256.30 0.347 ± 0.07
PALN14 70.86 ± 3.61 71.53 24.20 ± 1.56 26.02 251.5 ± 24.56 242.08 0.360 ± 0.07
PALN15 81.77 ± 6.41 81.06 22.83 ± 2.28 22.55 249.2 ± 16.87 246.42 0.344 ± 0.03
PALN16 86.09 ± 2.93 85.44 28.49 ± 1.76 28.10 157.5 ± 3.45 162.83 0.263 ± 0.01
PALN17 85.06 ± 2.88 85.44 27.69 ± 1.97 28.10 155.3 ± 7.65 162.82 0.228 ± 0.02
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chitosan, and PEG 2000 were observed. An endotherm
observed at 242.3°C was assigned to the left shift of the
ACV MP. Although the left shift was evidence for crystallin-
ity changes, the amplitude of shifting was abnormal. Table III
showed that heating rate for acyclovir and PM was higher
than PALN1. Higher heating rate results in MP shifted to a
higher temperature which is in agreement from the previous
report of acyclovir MP (40).
X-Ray Diffraction
Figure 5 b showed the ACV peaks at 2θ of 7.12°, 10.66°,
13.22°, 16.19°, 23.56°, 24.10°, 26.33°, and 29.44°, indicating
crystalline nature of the drug. Crystallinity index was
calculated based on (12) with the aids of OriginPro Graphing
& Analysis 2020 software. The ACV crystalline and total
peak area were found to be 53,181.75 and 56,443.52 unit area,
respectively, with crystallinity index calculated to be 0.9422,
which was very crystalline
CrystallinityIndex ¼ AreaCrystalline=AreaTotal ð12Þ
where AreaCrystalline and AreaTotal were integrated areas for
crystalline structure and total integrated area, respectively.
ACV peak was diminished from PM diffractogram. This
suggested possibility of ACV turned into the disordered
crystalline state due to the molecular interaction with lecithin
and chitosan. By comparing ACV and PALN1 diffractogram,
a broad peak emerged with sharp peak diminishment
indicating ACV entrapped in LPNPs system in the amor-
phous state of the nanoparticles (41).
Fig. 3. Three-dimensional (3-D) response surface plot showing effect of the independent factors on the depended responses
EE%, particle size, and zeta potential
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Attenuated Total Reflection-Fourier Transform Infrared
Figure 6 showed PEG 2000 characteristic peaks at
3409 cm−1 indicating intermolecular hydrogen-bonded hy-
droxyl group (O–H) asymmetric stretching. Peaks at
2945 cm−1, 2884 cm−1, and 2860 cm−1 are assigned to C–H
symmetrical stretching. C–H bending is observed at
2740 cm−1 (42). Peaks at 1240 cm−1, 1146 cm−1, 1099 cm−1,
and 1059 cm−1 are assigned to C–O–C stretching (43,44).
Chitosan’s broad peak at 3354 cm−1 and 3291 cm−1 are
indexed to NH2 stretching vibration. Peaks at 1651 cm
−1 and
1585 cm−1 are assigned to N–H bending of primary amine.
Peaks 1199 cm−1 and 1150 cm−1 are attributed to C–O
stretching of C–O–C. Two intense peaks at 1058 cm−1 and
1026 cm−1 indicate the presence of primary aliphatic amine
stretching of C–N overlapping with secondary cyclic alcohol
stretching of O–H 1 (42,43,45). A peak at 894 cm−1 is
attributed to the pyranoid ring of chitosan (46).
Lecithin’ IR spectrum displays characteristic N–H group
stretching at peak 3379 cm−1 (47). Symmetry stretching of C–
H for the cis-double bond is depicted at 3009 cm−1. Saturated
aliphatic ester carbonyl stretching (–C=O) is represented at
peak 1735 cm−1 (48). A strong, sharp peak at 1087 cm−1
shows a symmetric stretching of phosphate groups (42). The
asymmetric stretchings of P=O which overlapped with P–O
where both co-exist in phosphodiester group, together with
P–O–C stretching, were at peaks 1238 cm−1 and 1062 cm−1
respectively. The peak at 968 cm−1 is attributed to N+–(CH3)3
asymmetric stretching overlapped with O–P–O deformation
(49). Out of plane bending of HC–CN is depicted at 818 cm−1
(50).
Acyclovir IR spectrum shows intermolecular and intra-
molecular hydrogen-bonded hydroxyl group (O–H)
stretchings at 3515 cm−1 and 3470 cm−1 (51), while NH2
symmetrical stretching is at 3438 cm−1 (52). Secondary amine
stretching is at 3290 cm−1 (42). A peak at 3177 cm−1 is
attributed to N–H stretching overlapped with O–H stretching
(47). C–H and H–C–H stretchings are represented at
2927 cm−1 and 2854 cm−1 (42). The presence of C=O at
1708 cm−1, presence of C8–H together with ring vibration of
Fig. 4. SEM image of PALN1 at a × 12,000, b× 30,000, and HRTEM image of PALNs at c×
7800
Table 5. Statistical Analysis Results of Entrapment Efficiency, Particle Size, and Zeta Potential
Parameter Drug EE (%) Particle size (nm) Zeta potential (mV)
Coefficient p value Coefficient p value Coefficient p value
Intercept 85.4405 < 0.0001* 162.826 < 0.0001* 28.0896 < 0.0001*
X1 3.5735 0.0003* 16.2333 0.0054* − 3.5675 0.0050*
X2 − 3.8271 0.0002* 18.3916 0.0028* 8.6821 < 0.0001*
X3 − 2.0429 0.0064* 16.7166 0.0047* − 7.1571 < 0.0001*
X1X2 − 2.0193 0.0315* 14.4667 0.0410* 0.4175 0.7481
X1X3 1.1877 0.1588 − 14.0668 0.0454* 1.8325 0.1860
X2X3 − 1.9454 0.0363* − 15.65 0.0305* 2.0833 0.1395
X1
2 − 6.9129 < 0.0001* 17.3868 0.0178* 1.5143 0.2538
X2
2 − 4.3391 0.0006* 26.7035 0.0021* 6.6986 0.0009*
X3
2 − 0.1888 0.8044 47.3201 < 0.0001* 1.8436 0.1739
*p value less than 0.05
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guanine, was shown at 1483 cm−1, while the presence of
guanine structure was inferred at 1370 cm−1 (42).
The IR spectra of PM represent the combination of all
characteristic peaks, such as 2884 cm−1 and 2860 cm−1 (PEG
2000); 3354 cm−1 and 3291 cm−1 (chitosan); 3379 cm−1 and
3009 cm−1 (lecithin); and 3470 cm−1, 3438 cm−1, and
3177 cm−1(ACV). The peaks showed very slight shifting (±
5 cm−1), indicating no bonding interaction between drug and
other formulation ingredients. PALN1 was observed that
none of the ACV characteristic peaks emerged, indicating
encapsulation of the drug.
Stability Study of PALN1
Table VI displays the particle size of PALN1 at different
sampling time. The t tests were conducted with a p value
higher than 0.05 for all tests suggested that there was an
insignificant variation in PALN1 particle size on each
sampling time as compared with 0th day’s measurement.
The obtained results were in agreement with a PALN1 zeta
potential of 37.70 ± 1.16 mV which render the suspension
stable by avoiding particle aggregation due to strong surface
charge that repels each other. In brief, optimised formulations
exhibit good physical stability for up to 60 days. There was no
significant difference was observed p < 0.05.
In Vitro Drug Release
Figure 7 a and b showed ACV release profile in pH 1.2
(SGF) and pH 6.4 (SIF) respectively. Various kinetic models
were employed for a comprehensive understanding of drug
release mechanisms from the optimised formulation.
Table VII shows the values of correlation coefficient (r2)
and releasing model constant (k). Higuchi model showed the
best fit with the highest r2 value and can be concluded that the
PALN formulation showed modified release. This model
corresponds to the sustained release properties of lecithin-
chitosan nanoparticle. The drug release mechanism was
identified based on the diffusion constant, n, from
Korsmeyer-Peppas equation, as shown in Eq. (11). The
mathematical adjustment of Eqs. (13) and (14) was obtained:
Qt=QCR ¼ KKP tn ð13Þ
log10 Qt=QCRð Þ ¼ log10 KKPð Þ n log10t ð14Þ
where Qt and QCR indicate the amount of drug being
released at time t and after time ∞ respectively. n represents
the diffusional exponent and Kkp gives Korsmeyer release
rate constant. Based on the equation, the slope of
Korsemeyer-Peppas graph was the mechanism constant for
Higuchi model. With n values reported to be 0.6185 and
0.6103 for SGF and SIF, respectively, it was concluded that
PALN1 was following Higuchi drug releasing model with
non-Fickian transport.
Study of Ex Vivo Drug Permeability
Figure 7 c shows the cumulative percentage of drug
permeated against time. Table VIII shows that at the 10th
hour, only 58% of the drug was permeated to the releasing
media. The drug permeation profile had been prolonged due
to the smaller porosity and thicker intestinal membrane
compared with the dialysis membrane. The surface area of
the intestine accommodating formulation was 5 cm2.
Papp cm s−1
  ¼ 1:1626mg
10 60 60s 
1
5cm2  1mg=cm3
¼ 6:4589 10−6cm s−1
ð15Þ
Jss mg cm−2 s−1
  ¼ 6:4589 10−6cm s−1  1mg=cm3
¼ 6:4589 10−6mg cm−2 s−1 ð16Þ
Papp of 6.4589 × 10
−6 cm/s was a 3.2-fold improvement as
compared with reported value of 0.12 × 10−6 to 2.0 ×
10−6 cm s−1 (8). The optimised PALN formulation had the




acyclovir were successfully formulated with particle size less
than 200 nm, optimum PDI, entrapment efficiency greater
than 80%, and with positive zeta potential value greater than
+ 30 mV. SEM and HRTEM images showed the spherical
structure of the nanoparticle. FTIR analysis with the dimin-
ishment of all ACV characteristic peaks in formulation
Fig. 5. Characterisation of PALN nanoparticles. a DSC thermogram of PALNs, physical mixture, ACV,
lecithin, PEG 2000, chitosan; b XRD Diffractogram for PALNs
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Fig. 6. Stacked spectra of ATR-FTIR from 4000 to 600 cm−1 for PALNs, physical mixture, acyclovir, lecithin, chitosan, and PEG
2000
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spectrum indicates its encapsulation. DSC thermogram
depicted a left shift, evidencing acyclovir’s state changes from
crystalline to amorphous property. The obtained results is
further proved by the presence of a broad peak of PALN1
and diminishment of ACV crystalline peak in XRD
diffractogram. In vitro release profile of ACV in nanoparticles
had shown 24-h sustained release following Higuchi model
with non-Fickian mechanism in both SGF and SIF. Ex vivo
permeation study displayed a 3.2-fold improvement for
acyclovir’s apparent permeability. The formulation was stable
up to 60 days from the aspect of particle size. The results
demonstrated the ability of PEGylated lecithin-chitosan
nanoparticles not only in providing high encapsulation of
ACV and 24-h sustained release profile in both SGF and SIF,
but also in enhancing the permeability of ACV. These
findings suggested that PEGylated lecithin-chitosan
Table 6. Particle Size and Zeta Potential of PALNs at Each Sampling
Time
Day Particle size (nm) Zeta potential (mV)
0th 187.70 ± 3.75 37.94 ± 0.33
15th 193.80 ± 5.73 38.26 ± 0.40
30th 194.77 ± 2.05 38.22 ± 0.33
45th 184.37 ± 4.00 37.83 ± 0.26
60th 183.47 ± 4.47 37.32 ± 0.29
Fig. 7. ACV in vitro drug release profile in a pH 1.2, b pH 6.4, and c ACV intestinal permeation profile
Table 7. Coefficient of Determination r2 and Releasing Model
Constant K for Drug Releasing Models















Zero order 0.6184 3.1424 0.5605 3.0729
First order 0.9339 0.2588 0.7999 1.3440
Higuchi
model








0.0053 0.0131 0.0032 0.0100
The italicized is done to show the Nanoparticle release model is
folloing Higuchi release model. It is done just to make it more visible
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nanoparticles may be used for drugs with poor aqueous
solubility and permeability. Further, study on in vivo perfor-
mance should be conducted to assess the improvement in oral
bioavailability of ACV, as well as the applicability of this
formulation on other BCS class III drugs.
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